Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 7/20 | 0.50 |
| ▸ | SMAD3 | P84022 | 6/20 | 0.50 |
| ▸ | CFTR | P13569 | 10/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109016 | 0.94 | CFTR (0.47) | P4HBSMAD3CFTR | |
| SCHEMBL1073740 | 0.93 | CFTR (0.47) | P4HBSMAD3CFTR | |
| SCHEMBL4118830 | 0.92 | CFTR (0.46) | P4HBSMAD3CFTRTP53 | |
| SCHEMBL4116231 | 0.89 | CFTR (0.43) | CFTRTP53 | |
| SCHEMBL1067799 | 0.89 | CFTR (0.44) | CFTRTP53 | |
| SCHEMBL1067801 | 0.89 | CFTR (0.44) | CFTRTP53 | |
| SCHEMBL1071000 | 0.89 | CFTR (0.46) | CFTR | |
| SCHEMBL4120628 | 0.88 | CFTR (0.43) | CFTRTP53 | |
| SCHEMBL27825466 | 0.87 | TP53 (0.48) | P4HBSMAD3CFTRTP53 | |
| SCHEMBL1074831 | 0.85 | CFTR (0.51) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2980077-B1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2980077-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2980077-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2615085-B1 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMA (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2615085-B1 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8889875-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889875-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889875-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130317020-A1 | Pyridyl Derivatives as CFTR Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2271621-B1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120270869-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227615-B2 | Pyridyl derivatives as CFTR modulators | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2271621-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009123896-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009123896-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCC4, ABCB1 | P4HB 283/4885SMAD3 620/4885CFTR 1/4885 |
| US-20130317020-A1 | Pyridyl Derivatives as CFTR Modulators | CFTR, ABCC4, ABCB1 | P4HB 283/4885SMAD3 620/4885CFTR 1/4885 |
| US-20120270869-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCC4, ABCB1 | P4HB 283/4885SMAD3 620/4885CFTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.